ARRAY BIOPHARMA INC is a pharmaceutical company focused on Oncology, Metabolic. Key products include MEKTOVI.
FDA Novel Drug Designations
(2018)ARRAY BIOPHARMA INC at a Glance
- Fast trial execution (24 months median completion)
ARRAY BIOPHARMA INC's Key Drugs
ARRAY BIOPHARMA INC's core commercial portfolio centers on MEKTOVI, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
ARRAY BIOPHARMA INC's Recent FDA Approvals
New NDA/BLA approvals for ARRAY BIOPHARMA INC over the last two years — novel drugs only, excluding generics and label supplements.
ARRAY BIOPHARMA INC's Therapeutic Areas
ARRAY BIOPHARMA INC's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ARRAY BIOPHARMA INC's Top Competitors
ARRAY BIOPHARMA INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ARRAY BIOPHARMA INC Pipeline Snapshot
ARRAY BIOPHARMA INC has 6 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 5 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 24 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges